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AbstrACt
Introduction Surgery for oesophageal and gastric 
cancers is associated with high morbidity, mortality and 
poor quality of life postoperatively. The Finnish National 
Esophago-Gastric Cancer Cohort has been established 
with the aim of identifying factors that could contribute to 
improved outcomes in oesophago-gastric cancer.
Methods and analysis All patients with oesophageal and 
gastric cancer diagnosed in Finland between 1987 and 
2015 will be identified from the Finnish national registries. 
The Finnish Cancer Registry and Finnish Patient Registry 
will be used to identify patients that fulfil the inclusion 
criteria for the study: (1) diagnosis of oesophageal, gastro-
oesophageal junction, or gastric cancer, (2) any surgical 
treatment for the diagnosed cancer and (3) age of 18 
or over at the time of diagnosis. Clinical variables and 
complication information will be retrieved in extensive data 
collection from the medical records of the relevant Finnish 
hospitals and complete follow-up for vital status from 
Statistics Finland. Primary endpoint is overall all-cause 
mortality and secondary endpoints include complications, 
reoperations, medication use and sick leaves. Sub-studies 
will be implemented within the cohort to investigate 
specific populations undergoing oesophageal and gastric 
cancer surgery. The initial estimated sample size is 1800 
patients with surgically treated oesophageal cancer and 
7500 patients with surgically treated gastric cancer.
Ethics and dissemination The study has been approved 
by the Ethical Committee in Northern Ostrobothnia, Finland 
and The National Institute for Health and Welfare, Finland. 
Study findings will be disseminated via presentations at 
conferences and publications in peer-reviewed journals.
IntroduCtIon 
Gastric cancer is the third, and oesophageal 
cancer the sixth, leading cause of cancer 
death worldwide.1 The incidence of oesoph-
ageal adenocarcinoma is increasing, while 
that of oesophageal squamous cell carcinoma 
and gastric cancer is decreasing in Finland,2 
similar to other Western countries.3 The inci-
dence of gastric cancer is slowly decreasing in 
majority of the countries across the globe.4 
However, both cancers are characterised by 
poor survival even after curatively intended 
surgery5–8 and a ‘textbook outcome’ may 
be achieved in less than half of the patients 
undergoing oesophago-gastric cancer 
surgery.9 Studies on sick leaves,10 or postop-
erative use of opioids as an outcome after 
oesophageal and gastric cancer surgery are 
lacking, while these are important outcomes 
for the patients. It has been shown that sick 
leaves affect for example job retention in 
patients with cancer.11 
Randomised trials in oesophageal and 
gastric cancer have provided quality 
strengths and limitations of this study
 ► The main strength of the study is the popula-
tion-based design with complete and accurate as-
certainment and follow-up of all patients diagnosed 
with oesophageal or gastric cancer in Finland, coun-
teracting selection bias.
 ► The inclusion of multiple potential confounding fac-
tors from the registries and patient records allows 
accurate analysis of a variety of exposures and end 
points.
 ► The sample size will large enough to enable robust 
survival and regression analyses in smaller sub-
groups of patients.
 ► The main limitations of the study are the exclusion 
of patients not undergoing surgery and information 
lag of up to 2 years.
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evidence that neoadjuvant—and adjuvant therapies 
increase survival12–15 and that minimally invasive surgical 
approaches reduce, or at least do not increase compli-
cations.16 17 Despite their good internal validity and lack 
of bias, randomised controlled studies in general have 
limited external validity and applicability to general popu-
lation, and thus need to be complemented by quality 
observational studies to reliably assess the effects of imple-
mentation of trial results into practice.18 Additionally, 
observational studies can provide evidence on questions 
that have not, or cannot, be evaluated in randomised 
trials.18
In Finland, high-quality registry data on these cancers 
is readily available.19 Despite the good availability, the 
exposure and outcome data in the registries are not 
detailed enough for surgical research. Because of small 
population (5.5 million) sparsely populating Finland, 
the hospitals are many, and the single-centre cohorts 
containing detailed information are small, not neces-
sarily generalisable and have potential selection bias. 
There are no previous coordinated nationwide popula-
tion-based research efforts with detailed clinical data on 
oesophago-gastric cancer in Finland. To overcome these 
challenges, an extensive retrospective nationwide data 
collection from the patient medical records is needed. 
The Finnish National Esophago-Gastric Cancer Cohort 
(FINEGO) was established as a researcher-led effort to 
coordinate this retrospective database.
objectives
The specific objectives of the FINEGO are:
 ► To establish important baseline data on national and 
regional trends and changes over time in oesophageal 
and gastric cancer surgery, postoperative morbidity 
and long-term outcomes in Finland.
 ► To investigate associations between surgeon and 
hospital volume and postoperative morbidity and 
mortality in oesophago-gastric cancers.
 ► To assess the relevance of clinical characteristics, 
modifiable risk factors, such as preoperative feeding, 
surgical approach, type of neoadjuvant treatment, 
or method of analgesia in relation to mortality and 
morbidity outcomes, as well as cancer survivorship, 
such as postoperative medication use in oesopha-
go-gastric cancer.
 ► To investigate whether histological assessment could 
be used for prediction of prognosis in oesophageal 
and gastric cancer.
MEthods
A multicentre FINEGO-collaborative has been established 
to conduct large-scale epidemiological, clinical and clini-
copathological studies in oesophago-gastric cancers. The 
collaborative includes one to two senior consultants upper 
gastrointestinal or thoracic surgeons as the local principal 
investigators (PIs) from all academic centres conducting 
oesophageal and gastric cancer surgery in Finland, as 
well as senior consultant oesophago-gastric pathologists 
and biostatisticians. The participating researchers will 
sign the needed professional confidentiality consents 
to be allowed access to patient data obtained from the 
registries.
study design
This study is a population-based, nationwide, retrospective 
cohort study in Finland. The initial study period is from 
1 January 1987 to 31 December 2015, with follow-up until 
31 December 2016. The study period will be expanded 
every 5 years to keep the cohort updated for the most 
recent data.
Inclusion and exclusion criteria
The patients fulfilling the following inclusion criteria are 
included in the study:
1. Primary cancer of epithelial origin in the oesophagus, 
the gastro-oesophageal junction or the stomach.
2. Patient receives surgical treatment for the cancer, in-
cluding curative, palliative, rescue surgery that is, sur-
gery after curative chemoradiation, or endoscopic cu-
rative surgery, such as endoscopic mucosal resection 
and endoscopic submucosal dissection.
3. Age at least or over 18 years during the time of 
diagnosis.
Identification of the study participants
The immutable, 11-digit personal identification number 
assigned to each resident in the country allows reliable 
identification and combining the registry data with 
patient records.20 The patients will be identified through 
the Finnish Cancer Registry, and the Finnish Patient 
Registry by searching these registries for cancer diag-
noses (online supplementary table 1) and operation 
status and operations codes (online supplementary table 
2). The identification through both registries is done to 
ensure near 100% completeness on oesophago-gastric 
cancer diagnosis. The patients undergoing oesophageal 
or gastric cancer surgery will be identified using the oper-
ations codes in the Finnish Patient Registry. The Finnish 
Patient Registry will provide the hospital names and oper-
ation dates, based on which the relevant patient records 
will be retrieved from the archives of the hospitals in all 
21 hospital districts in Finland.
data collection
Registry data will be collected from The Finnish Cancer 
Registry, The Finnish Patient Registry, The Population Register 
Centre, Statistics Finland and The Social Insurance Institution 
(Kela)-registry (table 1). The quality of data in these regis-
tries is known to be very high21–24 and reporting to the 
registries is mandatory by the Finnish Law. These registry 
data include the identifying information, the variables 
related to the socio-economy, and will be used to calcu-
late the well-validated Charlson’s Comorbidity Index 
(online supplementary table 3)25 and annual hospital 
volumes. All registry data-derived variables are calculated 
by a biostatistician. The patient records of the included 
patients identified from the registries will be scrutinised by 
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the study nurses and the investigators using standardised 
forms for clinical variables, including patient characteris-
tics and surgeon, outcome and complication information 
(table 1 and online supplementary text 1). The clinical 
variables have been decided on by the investigators in 
the FINEGO group. Key variables, such as those from the 
operations charts will be extracted by one of the investiga-
tors, while the nurse extracts information not considered 
prone to errors, such as administrative data and laboratory 
results. All records and the corresponding data collection 
forms will be scanned and saved for later use. The histo-
logical samples will be collected from the biobanks. These 
original, prospectively collected diagnostic slides from 
the preoperative gastroscopy and the surgical specimen 
will be sought from the biobanks’ archives for the study 
patients. The sample slides are retrieved according to the 
biobank policies, and scanned and digitised into a picture 
form for assessment and review of the histological param-
eters and neoadjuvant treatment response (table 1).
The identifying information of the selected patients 
from each hospital district will be provided to the respec-
tive PIs and administrative personnel for obtaining the 
patient records data from the healthcare entities’ archives. 
The obtained registry data, medical and health records 
data, as well as the digitised histological samples, will 
be entered into the study database and pseudonymised 
using study identifiers after the completion of the data 
collection. The hard copies of some of the study data will 
be kept in a safe deposit on the premises of University of 
Oulu. The identification variables from the registries will 
be kept in an encrypted and password-protected file with 
limited access granted to only the main biostatistician and 
the PI of the project. The pseudonymised cohort without 
identifying information is available for the members of 
the collaborative for sub-studies within the framework 
specified below.
data management and analysis plan
The data management and analyses in this study will be 
supervised and conducted by an expert biostatistician 
(PO). After finishing the data collection, a cohort profile 
will be published. For the cohort profile, number of new 
yearly cancer cases and the yearly number of operated 
cancers will be calculated based on the registry data. 
The baseline characteristics, that is, number of patients 
in each group of selected variables will be reported in 
tables. Overall all-cause mortality will be reported for 
each cancer type based on the life table method26 and 
depicted using Kaplan-Meier curves.
Each of the sub-studies will be planned in the collabo-
rative with a detailed a priori study protocol describing 
the rationale, aims, hypothesis and statistical analysis plan 
including appropriate methods, potential confounding 
and biases for the particular research question, as well as 
the biostatistician involved in the analysis.
data quality assessment
The data quality in the registries will be checked through 
comparing the collected clinical data against the data, 
namely type of surgery and tumour stage obtained from 
the registries. Internal audit, where a random sample 
Table 1 Data sources and dataset information
Data source Variables
The Finnish Cancer 
Registry
Personal identification number 
(age, sex)
Diagnosis number
Date of cancer diagnosis
Tumour stage
The Finnish Patient 
Registry
Personal identification number 
(age, sex)
Hospital admissions data
 ► Admitting hospital
 ► Dates of admission and 
discharge
 ► Diagnosis codes
 ► Operations codes
The Population Register 
Centre
Marital status






 ► Type (Anatomical Therapeutic 
Chemical (ATC)-code)
 ► Date dispensed
 ► Amount of dispensed drug
Sick leave (start date, end date)
Pension information (start date)
Patient records Tumour stage information
Anaesthesia information
 ► Type of anaesthesia
 ► ASA classification*
Surgery information
 ► Type of surgery
 ► Surgeon volume
 ► Bleeding
 ► Operation duration
Complications




 ► Clavien-Dindo classification
Oncological treatment
 ► Neoadjuvant and adjuvant 
treatment
 ► Treatment modality
 ► Complications
Pathology
 ► Tumour location and stage
 ► Lymph node yield and 
resection radicality
Hospital and intensive care unit 
stay








pen: first published as 10.1136/bmjopen-2018-024094 on 15 January 2019. Downloaded from 
4 Kauppila JH, et al. BMJ Open 2019;9:e024094. doi:10.1136/bmjopen-2018-024094
Open access 
of the patient records of 50 patients with oesophageal 
cancer and 50 patients with gastric cancer will be re-re-
viewed by another investigator, and the differences 
between the two assessments will be checked against the 
original data collection. If there are signs of difficulties in 
the assessment of certain variables or systematic errors, 
these variables will be audited in more detail. As of now, 
no external audit is planned, but all study protocols, data 
files, statistical syntax used to obtain the results and the 
end-product will be kept for further potential audits.
sample size
One of the main strengths is the large sample size of 
the study. It is estimated that at least 6000 oesophageal 
and 25 000 patients with gastric cancer will be found in 
screening during the study period. Of these patients, esti-
mated 30% have been operated for their cancer, yielding 
estimates of 1800 oesophageal and 7500 patients with 
gastric cancer for the study.
With 1800 patients with oesophageal cancer, the esti-
mated power would be >80% to reliably detect weak 
associations (HR =1.15), given an equal distribution of 
patients in the exposure groups. With 7500 patients with 
gastric cancer, the power would be >80 to detect an associ-
ation at the level HR=1.07.
Permissions and registration
Relevant local permissions and registrations are obtained 
by the collaborative from all the 21 hospital districts, 
namely the Lapland Hospital district, Länsi-Pohja Hospital 
District, Kainuun Social and Health Care Joint Authority, 
The Hospital district of Northern Ostrobothnia, Soite, 
The Hospital District of South Ostrobothnia, Pirkanmaa 
Hospital District, Kanta-Häme Hospital District, Vaasa 
Hospital District, Satakunta Hospital District, Hospital 
District of Southwest Finland, Ålands hälso- och sjukvård, 
Joint Authority of the Helsinki and Uusimaa Hospital 
District, Päijät-Häme Hospital District, Kymenlaakso 
Social and Health Services Care, South Karelia Social 
and Health Care District (Eksote), North Karelia Central 
Hospital and Honkalampi Centre, East Savo Hospital 
District, South Savo Social and Health Services, Kuopio 
University Hospital District and The Central Finland 
Hospital District, as well as the relevant Biobanks, namely 
Auria Biobank, Helsinki Biobank, Biobank of Eastern 
Finland, Central Finland Biobank, Northern Finland 
Biobank Borealis and Finnish Clinical Biobank Tampere.
Individual informed consent will not be sought from 
the patients whose data are used in this observational 
study. Obtaining the informed consent has been waived 
by the Finnish law. The study will be conducted in accor-
dance with the Declaration of Helsinki.
Patient and public involvement
Patients or public were not involved in the development 
of the research question and study design or conducting 
the present study.
dIsCussIon
Oesophageal and gastric cancers have poor prognosis, 
even after curative surgery.5 6 The present popula-
tion-based, nationwide retrospective cohort study will 
provide information on the recent time trends in the 
treatment of oesophageal and gastric cancer and identify 
new, and verify previously identified, modifiable factors 
related to morbidity, mortality and survivorship after 
oesophageal and gastric cancer surgery.
The strengths of the FINEGO-cohort include its popu-
lation-based design with complete and accurate ascer-
tainment and follow-up of all patients diagnosed with 
oesophageal or gastric cancer in Finland, counteracting 
selection bias. The combined use of registry and patient 
records data reduces information bias. The inclusion of 
multiple potential confounding factors from the registries 
and patient records allows accurate analysis of a variety 
of exposures and end points. The sample size will large 
enough to enable robust survival and regression analyses 
in smaller sub-groups of patients. Compared with some 
global collaboratives, such as the Worldwide Esophageal 
Cancer Collaboration27 or Esophagectomy Complications 
Consensus Group,28 the FINEGO can contribute to the 
scientific community by producing results in a real-life 
setting including all patients operated for oesophageal 
and gastric cancers in the country, while the collabora-
tives typically include a sample of patients operated in 
high-volume centres. Furthermore, the above-mentioned 
collaboratives include only oesophageal cancer, while 
the present study includes both oesophageal and gastric 
cancer.
There are also limitations in the present study. The 
retrospective study design is potentially weaker in data 
quality, compared with a prospective study. However, the 
retrospective design enables obtaining a large number 
of patients more quickly than a prospective data collec-
tion, and the data quality in the registries the cohort is 
based on is known to be very high, and the manually 
collected patient records data will be vigorously checked 
and validated for quality. Furthermore, a national quality 
registry for these patients is going to be established, and 
the prospective clinical data collected in that quality 
registry can be later used in the updates of the FINE-
GO-cohort to potentially improve the quality of the more 
recent data. All patients not undergoing surgery will be 
excluded, because examining the patient records for 
all the patients would increase the number of involved 
healthcare entities significantly to over 250, reducing 
the feasibility of the data collection. Patients undergoing 
curatively intended or palliative chemotherapy and/or 
radiotherapy will be excluded, reducing the possibilities 
to study patients with disseminated disease or not eligible 
for any type of surgery. The cohort is planned to be 
updated every 5 years, and there is a lag of up to 2 years, 
including quality checks and controls, before the registry 
data is made available for research, preventing the study 
group from getting the most recent data for analysis 
even during the cohort updates. However, this lag will 
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not reduce the relative sample size considerably and the 
effect on follow-up in person-years is minimal due to high 
mortality rates of the cancers. Furthermore, there are 
some variables, including smoking history and alcohol 
use, that are not recorded in the registries and cannot be 
reliably retrieved from the patient records, as they are not 
routinely recorded by the healthcare personnel in a struc-
tured way. However, the data quality and missing data will 
be meticulously checked before running the sub-studies, 
and the missing data will be taken into account by using 
multiple imputation methods in the analyses to reduce 
bias from missing data.
Taken together, this population-based, nationwide 
retrospective cohort study will provide new evidence 
regarding various unanswered questions in oesophageal 
and gastric cancer surgery by combining epidemiolog-
ical and clinical data, as well as complement randomised 
clinical trials by assessing their findings in an unselected 
population.
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